Patents by Inventor Joseph Strupczewski

Joseph Strupczewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
    Publication number: 20070161641
    Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates is to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Application
    Filed: March 5, 2007
    Publication date: July 12, 2007
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: James Hendrix, Horst Hemmerle, Matthias Urmann, Gregory Shutske, Joseph Strupczewski, Kenneth Bordeau, John Jurcak, Thaddeus Nieduzak, Sharon Jackson, Paul Angell, James Carey, George Lee, David Fink, Jean-Francois Sabuco, Yulin Chiang, Nicola Collar
  • Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
    Publication number: 20070142351
    Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.
    Type: Application
    Filed: December 21, 2006
    Publication date: June 21, 2007
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: James Hendrix, Joseph Strupczewski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerte, John Jurcak, Harpal Gill, Franz Weiberth, Thaddeus Nieduzak, Sharon Jackson, Xu-Yang Zhao, Paul Mueller
  • Method of treating pain and hypertension
    Patent number: 4031221
    Abstract: 3-[2-(Phenyloxycycloazalkyl)ethyl]indoles possessing antihypertensive, analgesic, and tranquilizing properties and process for their preparation are described.
    Type: Grant
    Filed: June 19, 1975
    Date of Patent: June 21, 1977
    Assignee: American Hoechst Corporation
    Inventors: Grover C. Helsley, Joseph Strupczewski